Beyond Barriers

A novel technology platform
for the delivery of therapeutics
across biological barriers

TECHNOLOGY INVESTORS
Gate2Brain

The solution

Gate2Brain
Technology

Gate2Brain (G2B) uses a novel technology platform for the delivery of therapeutics. Our platform is based on three families of peptide shuttles that improve the biopharmaceutical properties of cargoes such as small molecules, peptides, nanoparticles, proteins and antibodies in vitro and in vivo when conjugated to them.

The G2B technology platform is applicable to therapeutic areas in which biological barriers hinder the delivery and activity of drugs.

Read more

About us

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.

Read more
Link to: Technology
Technology

Gate2Brain (G2B) has a proprietary novel technology platform for the delivery of therapeutics across biological barriers.

Link to: Pipeline-Proof of Concept
Pipeline and Therapeutic Proof of Concept

G2B-002, the first therapeutic proof of concept of our technology platform, is aimed mainly at the treatment of rare pediatric solid tumors.

Link to: Investors
Investors

A strong network of investors ensures funding to achieve our goals.

Medicines beyond barriers

We go beyond physiological and disease barriers, as our portfolio of peptide shuttles cover barriers such as the blood-brain,
blood-retinal, skin and tumor barriers. We go beyond economic barriers, such as the lack of investment for the development of pediatric drugs. We go beyond societal barriers to provide medicines for everyone, everywhere.

Clinical Focus

Therapeutic
Proof of Concept

Our G2B therapeutic-peptide shuttle conjugates carry the drug cargo candidates to the target site in which the disease arises. G2B-002, our flagship product and proof of concept of the technology, offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare pediatric cancers.

Our objective is for G2B-002 to reach Phase 1 clinical trials and thus have a high social impact focused on the unmet medical needs of oncology, pediatric and rare diseases.

G2B-002 shows potent preclinical activity for rare pediatric cancer indications such as pediatric high-grade gliomas, DIPG, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma.

READ MORE
Gate2Brain

News & Media

Welcome to our news section, which provides a selection of our coverage in the media, industry, latest developments, plus videos, and more.

BIO EUROPE 2022GATE2BRAIN

Gate2Brain at BIO-EUROPE 2022

Gate2Brain will participate in the next edition of BIO-EUROPE, held in-person, from October 24 to 26,…
Read more
Pediatric Innovation Dayi4kids

G2B at Pediatric Innovation Day 2022

Yesterday we attended the Pediatric Innovation Day 2022 organized by i4kids, presenting our first indication,…
Read more
The Barcelona Deep Tech Award is part of the Barcelona Deep Tech Node initiative, which aims to support deep tech startups and spin-offs by facilitating their access to the market and international projection 🌐 and fostering the Deep Tech ecosystem in Barcelona.Barcelona Activa

Gate2Brain finalist in the Barcelona Deep Tech Award

,
Gate2Brain has been selected finalist in the Barcelona Deep Tech Awards together with the four startups:…
Read more
VII SEQT Summer School “Medicinal Chemistry and Chemical Biology in Drug DiscoveryGate2Brain

Gate2Brain at the VII SEQT Summer School

Our CEO, Meritxell Teixidó, participated as a speaker to the VII SEQT Summer School “Medicinal Chemistry…
Read more
internship Eada

EADA Master students at Gate2Brain

As part of their International Master in Management and International Master in Pharmaceutical and Biotechnology…
Read more
Nadia Calviño, First Vice President of the Government and Minister of Economic Affairs visits Gate2BrainSJD

Nadia Calviño, First Vice President of the Government visits Gate2Brain

Nadia Calviño, First Vice President of the Government and Minister of Economic Affairs, and Maria Eugènia…
Read more
Thank you for inviting Gate2Brain last Friday to the conference "DIGITALIZING AND REINDUSTRIALIZING SPAIN WITH THE RECOVERY PLAN". The purpose of this conference, focused on the digital axis of the Recovery Plan, was to give visibility to some of the digitization projects that have already received funding from the Plan in different areas and that are already contributing to this transformation, as well as to present the evolution of the Digital Spain agenda.Asuntos Económicos y transformación digital

Gate2Brain at “Digitalizing and reindustrializing Spain with the recovery plan”

Gate2Brain last Friday at the conference "DIGITALIZING AND REINDUSTRIALIZING SPAIN WITH THE RECOVERY…
Read more
It’s Gate2Brain second anniversary!! 🎂 The creativity, work and dedication of Gate2Brain's team can only be matched with its desire to bring medicines beyond barriers.Gate2Brain

Gate2Brain second anniversary

It’s Gate2Brain second anniversary!! The creativity, work and dedication of Gate2Brain's team can…
Read more
Gate2Brain participated on June 29 at The Milner Therapeutics Institute (MTI) Pitch Day 🗣️at the University of Cambridge, the cradle of cancer research. The MTI Pitch Day is a great initiative designed to highlight companies like us to investors, to create connections between academic entrepreneurship and investment to promote therapeutic companies. A great event that pulls together on one side academic, preclinical and research and on the other industry in an effort to push forward collaborative drug development and increase the standard of patient care

Gate2Brain at MIT Pitch Day at University of Cambridge

Gate2Brain participated on June 29 at The Milner Therapeutics Institute (MTI) Pitch Day at the University…
Read more
NEWS & MEDIA

1
2
Gate2Brain
1

Making therapies a reality for patients by addressing unmet medical needs.

2

Improving patients’ quality of life using a technology that provides superior drug transport efficacy.

Go Beyond Barriers & Contact Us

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social